KR101507717B1 - Ｐｄｅ4 억제제로서 유용한 치환된 아세토페논 - Google Patents

Ｐｄｅ4 억제제로서 유용한 치환된 아세토페논 Download PDF

Info

Publication number
KR101507717B1
KR101507717B1 KR1020097015481A KR20097015481A KR101507717B1 KR 101507717 B1 KR101507717 B1 KR 101507717B1 KR 1020097015481 A KR1020097015481 A KR 1020097015481A KR 20097015481 A KR20097015481 A KR 20097015481A KR 101507717 B1 KR101507717 B1 KR 101507717B1
Authority
KR
South Korea
Prior art keywords
compound
pyridin
dichloro
phenyl
dimethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020097015481A
Other languages
English (en)
Korean (ko)
Other versions
KR20090098990A (ko
Inventor
야콥 펠딩
시몬 펠드벡 닐센
Original Assignee
레오 파마 에이/에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 레오 파마 에이/에스 filed Critical 레오 파마 에이/에스
Publication of KR20090098990A publication Critical patent/KR20090098990A/ko
Application granted granted Critical
Publication of KR101507717B1 publication Critical patent/KR101507717B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020097015481A 2006-12-22 2007-12-21 Ｐｄｅ4 억제제로서 유용한 치환된 아세토페논 Expired - Fee Related KR101507717B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US87168906P 2006-12-22 2006-12-22
US60/871,689 2006-12-22
US94547007P 2007-06-21 2007-06-21
US60/945,470 2007-06-21
PCT/DK2007/000564 WO2008077404A1 (en) 2006-12-22 2007-12-21 Substituted acetophenones useful as pde4 inhibitors

Publications (2)

Publication Number Publication Date
KR20090098990A KR20090098990A (ko) 2009-09-18
KR101507717B1 true KR101507717B1 (ko) 2015-04-08

Family

ID=39156588

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097015481A Expired - Fee Related KR101507717B1 (ko) 2006-12-22 2007-12-21 Ｐｄｅ4 억제제로서 유용한 치환된 아세토페논

Country Status (23)

Country Link
US (3) US8148537B2 (enExample)
EP (1) EP2125736B1 (enExample)
JP (1) JP5342451B2 (enExample)
KR (1) KR101507717B1 (enExample)
AT (1) ATE503742T1 (enExample)
AU (1) AU2007336538B2 (enExample)
BR (1) BRPI0721113A2 (enExample)
CA (1) CA2673370C (enExample)
CR (1) CR10877A (enExample)
CY (1) CY1111596T1 (enExample)
DE (1) DE602007013617D1 (enExample)
DK (1) DK2125736T3 (enExample)
GT (1) GT200900172A (enExample)
HR (1) HRP20110464T1 (enExample)
IL (1) IL199383A (enExample)
MX (1) MX2009006593A (enExample)
MY (1) MY146022A (enExample)
NO (1) NO20092372L (enExample)
NZ (1) NZ577863A (enExample)
PL (1) PL2125736T3 (enExample)
PT (1) PT2125736E (enExample)
RU (1) RU2493149C2 (enExample)
WO (1) WO2008077404A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012007225A (es) 2009-12-22 2012-07-30 Leo Pharma As Composicion farmaceutica que comprende mezcla de solventes y derivado o analogo de vitamina d.
WO2011076207A2 (en) 2009-12-22 2011-06-30 Leo Pharma A/S Cutaneous composition comprising vitamin d analogue and a mixture of solvent and surfactants
PL2515874T3 (pl) 2009-12-22 2015-01-30 Leo Pharma As Nanokryształy jednowodnego kalcypotriolu
CN102775345A (zh) * 2011-05-13 2012-11-14 上海特化医药科技有限公司 制备罗氟司特的方法及中间体
CN104822392B (zh) * 2012-11-30 2017-09-08 利奥制药有限公司 抑制活化的t‑细胞中il‑22表达的方法
WO2014096018A1 (en) * 2012-12-19 2014-06-26 Leo Pharma A/S Methods for the preparation of substituted acetophenones
BR112016008161B1 (pt) * 2013-10-22 2022-11-29 Chiesi Farmaceutici S.P.A Processos para preparar um composto, compostos intermediários, forma cristalina de um composto, uso de uma forma cristalina de um composto e solvato de um composto
BR112016029510A2 (pt) 2014-06-23 2017-08-22 Leo Pharma As métodos para a preparação de um composto, e, composto intermediário.
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
PT3390407T (pt) 2015-12-18 2023-11-03 Union Therapeutics As Métodos para a preparação de compostos heterocíclicos de 1,3-benzodioxole
KR101702648B1 (ko) * 2016-05-10 2017-02-03 주식회사 엑티브온 피부 외용제용 보존제, 이를 포함하는 화장료 조성물 및 약학 조성물
MX394835B (es) 2017-06-20 2025-03-24 Union Therapeutics As Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol.
EP3838967A1 (en) 2019-12-16 2021-06-23 Spago Nanomedical AB Immobilization of phenolic compounds
CN117924243B (zh) * 2024-01-16 2025-09-12 沈阳药科大学 一种喹啉衍生物及其药用组合物和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995020578A1 (en) 1994-01-26 1995-08-03 Rhone-Poulenc Rorer Limited SUBSTITUTED AROMATIC COMPOUNDS AS c.AMP PHOSPHODIESTERASE- AND TNF-INHIBITORS
EP0943613A1 (en) * 1996-11-19 1999-09-22 Kyowa Hakko Kogyo Kabushiki Kaisha Oxygenic heterocyclic compounds
WO2006135828A2 (en) * 2005-06-10 2006-12-21 Memory Pharmaceuticals Corporation Trisubstituted amines as phosphodiesterase 4 inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW263495B (enExample) * 1992-12-23 1995-11-21 Celltech Ltd
US6514996B2 (en) * 1995-05-19 2003-02-04 Kyowa Hakko Kogyo Co., Ltd. Derivatives of benzofuran or benzodioxole
ES2258775T3 (es) * 1995-05-19 2006-09-01 Kyowa Hakko Kogyo Co., Ltd. Compuestos heterociclicos que contienen oxigeno.
RU2005131943A (ru) * 2003-03-17 2006-03-20 Киова Хакко Когио Ко., Лтд. (Jp) Лечебные и/или профилактические средства для хронических болезней кожи
WO2006040645A1 (en) * 2004-10-11 2006-04-20 Ranbaxy Laboratories Limited N-(3,5-dichloropyridin-4-yl)-2,4,5-alkoxy and 2,3,4-alkoxy benzamide derivatives as pde-iv (phophodiesterase type-iv) inhibitors for the treatment of inflammatory diseases such as asthma

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995020578A1 (en) 1994-01-26 1995-08-03 Rhone-Poulenc Rorer Limited SUBSTITUTED AROMATIC COMPOUNDS AS c.AMP PHOSPHODIESTERASE- AND TNF-INHIBITORS
EP0943613A1 (en) * 1996-11-19 1999-09-22 Kyowa Hakko Kogyo Kabushiki Kaisha Oxygenic heterocyclic compounds
WO2006135828A2 (en) * 2005-06-10 2006-12-21 Memory Pharmaceuticals Corporation Trisubstituted amines as phosphodiesterase 4 inhibitors

Also Published As

Publication number Publication date
ATE503742T1 (de) 2011-04-15
US20100035908A1 (en) 2010-02-11
US8324394B2 (en) 2012-12-04
US20130012716A1 (en) 2013-01-10
RU2009128191A (ru) 2011-01-27
HRP20110464T1 (hr) 2011-07-31
EP2125736A1 (en) 2009-12-02
IL199383A (en) 2015-02-26
AU2007336538B2 (en) 2012-04-05
JP2010513334A (ja) 2010-04-30
KR20090098990A (ko) 2009-09-18
EP2125736B1 (en) 2011-03-30
US8497380B2 (en) 2013-07-30
CA2673370C (en) 2015-11-17
DE602007013617D1 (de) 2011-05-12
CY1111596T1 (el) 2015-10-07
NO20092372L (no) 2009-07-14
MX2009006593A (es) 2009-07-02
RU2493149C2 (ru) 2013-09-20
CA2673370A1 (en) 2008-07-03
CR10877A (es) 2009-07-10
GT200900172A (es) 2011-10-05
PL2125736T3 (pl) 2011-09-30
JP5342451B2 (ja) 2013-11-13
MY146022A (en) 2012-06-15
BRPI0721113A2 (pt) 2014-10-07
AU2007336538A1 (en) 2008-07-03
WO2008077404A1 (en) 2008-07-03
PT2125736E (pt) 2011-07-01
US20120165539A1 (en) 2012-06-28
US8148537B2 (en) 2012-04-03
DK2125736T3 (da) 2011-07-11
HK1135392A1 (en) 2010-06-04
NZ577863A (en) 2012-04-27

Similar Documents

Publication Publication Date Title
KR101507717B1 (ko) Ｐｄｅ4 억제제로서 유용한 치환된 아세토페논
KR102662215B1 (ko) 치환된 피라졸로(1,5-a)피리미딘 및 의학적 장애의 치료에서의 그의 용도
JP4054368B2 (ja) 置換メチルアリール又はヘテロアリールアミド化合物
JP4054369B2 (ja) オルト置換アリールまたはヘテロアリールアミド化合物
JP4116058B2 (ja) プロスタグランジンｅ２拮抗薬としてのフェニルまたはピリジルアミド化合物
DE69403823T2 (de) Substituierte Phenylsulfonamine als selektive B3-Agonisten zur Behandlung von Diabetes und Fettleibigkeit
WO1998045268A1 (en) Nicotinamide derivatives
US8785474B2 (en) Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them, and use thereof to treat pain and other conditions
JP2006524687A (ja) バニロイド受容体で阻害活性を示す新規複素環アミド
CN101611005B (zh) 用作pde4抑制剂的取代的苯乙酮类
JP2003522771A (ja) Ｔｎｆおよびｐｄｅ−ｉｖ阻害剤としてのベンゾオキサゾール誘導体
HK1135392B (en) Substituted acetophenones useful as pde4 inhibitors
RS51736B (sr) Supstituisani acetofenoni korisni kao inhibitori pde4
TWI429433B (zh) 可供治療使用之經取代苯乙酮化物
AU2012203892A1 (en) Substituted acetophenones useful as PDE4 inhibitors

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20180309

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20190314

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20200327

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20200327